Trials / Completed
CompletedNCT05681273
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
A Phase I Study to Evaluate the Drug-Drug Interaction of Chiglitazar With Empagliflozin，Atorvastatin and Valsartan in Healthy Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiglitazar | Chiglitazar 48mg |
| DRUG | Empagliflozin | Empagliflozin 10mg |
| DRUG | Atorvastatin | Atorvastatin 20mg |
| DRUG | Valsartan | Valsartan 160mg |
Timeline
- Start date
- 2023-02-17
- Primary completion
- 2023-03-21
- Completion
- 2023-03-21
- First posted
- 2023-01-12
- Last updated
- 2023-06-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05681273. Inclusion in this directory is not an endorsement.